A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors

NCT02667873 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
72
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Stemline Therapeutics, Inc.